drugset
drugset / Trial / NCT01908192

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192 ↗

Phase 2/3 Terminated 60 enrolled SyneuRx International (Taiwan) Corp
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.

Timeline

Start
2014-06
Primary completion
2023-10-26
Completion
2023-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject NaBen® Unknown 500 mg Oral

Indications

schizophrenia